US 11214802
RNAi agents for inhibiting expression of alpha-ENaC and methods of use
granted A61PA61P5/40
Quick answer
US patent 11214802 (RNAi agents for inhibiting expression of alpha-ENaC and methods of use) held by Arrowhead Pharmaceuticals, Inc. expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Arrowhead Pharmaceuticals, Inc.
- Grant date
- Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 42
- CPC classes
- A61P, A61P5/40